2003; baxter - Supplements - Haematologica

More documents

Recommendations

Info

54J.G. Gilles(FVIII-KO mice and SCID mice) are now ongoingto evaluate how anti-FVIII production can becontrolled by an anti-Id immune response, andmore precisely, to design and evaluate new formsof specific idiotype-base therapies.References1. Briet E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K,Vermylen J, et al. High titer inhibitors in severehaemophilia A. A meta-analysis based on eight longtermfollow-up studies concerning inhibitors associatedwith crude or intermediate purity factor VIII products.Thromb Haemost 1994; 72:162-4.2. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M,Gungor T, et al. Incidence of development of factor VIIIand factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-8.3. Saint-Remy JM, Jacquemin MG, Gilles JG. Anti-idiotypicantibodies: from regulation to therapy of factorVIII inhibitors. Vox Sang 1999; 77 Suppl 1:21-4.4. Gilles JG, Vanzieleghem B, Saint-Remy JM. Factor VIIIInhibitors. Natural autoantibodies and anti-idiotypes.Semin Thromb Hemost 2000; 26:151-5.5. Algiman M, Dietrich G, Nydegger UE, Boieldieu D, SultanY, Kazatchkine MD. Natural antibodies to factorVIII (anti-hemophilic factor) in healthy individuals.Proc Natl Acad Sci USA 1992; 89:3795-9.6. Gilles JG, Saint-Remy JM. Healthy subjects produce bothanti-factor VIII and specific anti-idiotypic antibodies. JClin Invest 1994; 94:1496-505.7. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-RemyJM. Neutralizing antiidiotypic antibodies to factor VIIIinhibitors after desensitization in patients with hemophiliaA. J Clin Invest 1996; 97:1382-8.8. Gilles JG, Arnout J, Peerlinck K, Vermylen J, Saint-RemyJM. Antigen-antibody complexes made of FVIII andautologous specific antibodies down-regulate the productionof anti-FVIIIantibodies. XXI International Congressof the World Federation of Haemophilia 1994April; [abstract].9. Gilles JG, Vanzieleghem B, Saint-Remy JM. Animalmodels to explore mechanisms of tolerance induction toFVIII: SCID mice and SCID-FVIII-KO mice. Haematologica2000; 85 Suppl 10:103-7.10. Vanzieleghem B, Gilles JG, Desqueper B, Vermylen J,Saint-Remy JM. Humanized severe combined immunodeficientmice as a potential model for the study of toleranceto factor VIII. Thromb Haemost 2000; 83:833-9.11. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodiesin pooled normal human polyspecific Ig. JImmunol 1989; 143:4104-9.12. Sultan Y, Kazatchkine MD, Maisonneuve P, NydeggerUE. Anti-idiotypic suppression of autoantibodies to factorVIII (antihaemophilic factor) by high-dose intravenousgammaglobulin. Lancet 1984; 2:765-8.13. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C,et al. Tumor-specific, cytotoxic T-lymphocyte responseafter idiotype vaccination for B-cell, non-Hodgkin'slymphoma. Blood 1996; 88:580-9.14. Jacquemin MG, Desqueper BG, Benhida A, Vander ElstL, Hoylaerts MF, Bakkus M, et al. Mechanism and kineticsof factor VIII inactivation: study with an IgG4 monoclonalantibody derived from a hemophilia A patientwith inhibitor. Blood 1998; 92:496-506.15. Jacquemin M, Benhida A, Peerlinck K, Desqueper B,Vander Elst L, Lavend'homme R, et al. A human antibodydirected to the factor VIII C1 domain inhibits factorVIII cofactor activity and binding to von Willebrandfactor. Blood 2000; 95:156-63.haematologica vol. 88(supplement n. 12):september 2003
[Immunobiology of Tolerance Induction]review paperMurine models for the study offactor VIII inhibitorshaematologica 2003; 88(suppl. n. 12):55-63http://www.haematologica.org/free/immunotolerance2001.pdfBIRGIT M. REIPERT,*° MARIA SASGARY,* CHRISTINA HAUSL,°ELISABETH MAIER,* RAFI U. AHMAD,* PETER L. TURECEK,*HANS P. SCHWARZ*°*Baxter BioScience, Vienna, Austria; °Center forBioMolecular Therapeutics, Vienna, AustriaCorrespondence: Hans Peter Schwarz, MD, Baxter,BioScience Industriestraße 67 A-1220 Vienna, Austria.Phone: international +43.1.20100-2067. Fax: international+43.1.20100-525. E-mail: schwarh@baxter.comRegulation of the immune response to a complexprotein antigen like factor VIII (FVIII)requires interaction between different typesof immune cells and migration of these cellsbetween several compartments of the immunesystem. Access to such cells and the compartmentsthey traverse is limited in humans for obviousethical reasons. Hence, in vivo animal modelsare needed to understand the mechanisms ofantibody formation and to develop new therapeuticapproaches for inducing immune toleranceto FVIII in humans. As imperfect as any animalmodel is, important advances in human therapyhave resulted from appropriate use of suchmodels. Our present knowledge of how neutralizingantibodies develop against FVIII is based predominantlyon clinical findings in hemophilicpatients. The presence of FVIII inhibitors makespatients refractory to replacement therapy and is,therefore, a serious complication of modern treatment.The risk of patients with severe hemophiliaA developing anti-FVIII antibodies is clearlyassociated with the type of FVIII gene mutationthey have. Patients affected with nonsense mutations,large deletions and intrachromosomalrecombinations (inversions) in the FVIII geneshow the highest inhibitor incidence 1-3 (HAM-STeRS: The hemophilia A mutation, structure,test, resource site: http://europium.csc.mrc.ac.uk).These mutations are predicted to cause a completedeficit of any endogenous FVIII production.Therefore, human FVIII is probably a protein foreignto the immune system in these patients.Other mutations such as missense mutations andsmall deletions are associated with a much lowerincidence of inhibitor formation. 1-3 In these cases,non-functional FVIII antigen may circulate inthe blood 4 and render the immune system tolerantto the mutant FVIII protein. Native FVIII, presentin FVIII products could, therefore, be recognizedas an altered self protein by the immunesystem in these patients. Apart from the type ofFVIII gene mutation, other genetic factors such asthe HLA haplotype seem to be important for thedevelopment of FVIII inhibitors. To investigatehow important the HLA haplotype is in an animalmodel, animals with different genetic backgrounds,e.g. different inbred strains of mice, areneeded.The application route and dose of an antigendetermines the subsequent immune response. Inpatients, FVIII is given intravenously. Therefore,the spleen is probably the major location for thedevelopment of anti-FVIII immune responses.An animal model should reflect this and developdetectable anti-FVIII immune responses afterintravenous injection of FVIII doses equivalent tothe doses used for patients.Factor VIII is a protein antigen with some extrafeatures that distinguish it from other proteinantigens. In its activated form, activated FVIII(FVIIIa), is an essential cofactor in blood coagulation.In the presence of negatively chargedphospholipids, FVIIIa directly interacts with theserine protease factor IXa and forms a complexthat converts factor X into activated factor X(factor Xa). Factor Xa, in the presence of activatedfactor V (factor Va), phospholipids andcalcium ions, is then able to convert prothrombinto its active enzymatic form, thrombin. Apartfrom their function in blood coagulation, bothfactor Xa and thrombin have been shown in vitroto activate one or more of the protease-activatedreceptors (PAR receptors) expressed onendothelial cells. 5-7 This activation inducesproinflammatory stimuli. Therefore, each timeFVIII is given it is possible that it induces proinflammatorystimuli that directly influence theregulation of the immune response to FVIII. Ananimal model in which a severe bleeding diathesisis associated with a lack of FVIII would beoptimal for immunological studies.Given the diversity of the disease and the heterogeneityof the genetic background of thepatients with hemophilia A, who develop anti-FVIII antibodies, no single animal model couldcover all aspects of the immune response againstFVIII. Therefore, different models are needed toresearch the various facets of the response.Murine models in which the mechanism andhaematologica vol. 88(supplement n. 12):september 2003
Page 2 and 3:
haematologicahinformation for autho
Page 4 and 5:
haematologicahImmunobiology of Tole
Page 6 and 7:
[Molecular Genetics]review paperGen
Page 8 and 9: [Molecular Genetics]review paperGen
Page 10: 6R.C.R. LjungTable 2. Int database
Page 17 and 18: IV International Workshop on Immune
Page 33 and 34: [Round Table on Immune Tolerance Tr
Page 49 and 50: [Round Table on Immune Tolerance Tr
Page 57: IV International Workshop on Immune
Page 73 and 74: [New Aspects in Treatment of Hemoph
Page 97 and 98: [Acquired Inhibitors in Non-Hemophi
Page 109 and 110:
IV International Workshop on Immune
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
[Gene Therapy]review paperThe host
Page 117 and 118:
Page 119 and 120:
[Gene Therapy]review paperGene ther
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Index of authorsAhmad, R.U., 56Albe
show all

2003; baxter - Supplements - Haematologica

Create successful ePaper yourself

Delete template?

Save as template?